PREVIOUS QUESTION:

 

NEXT QUESTION:

 

What are issues in the length of treatment for prostate cancer?

ANSWER

The disagreement in this situation is between continuous androgen deprivation (hormone therapy) and intermittent androgen deprivation. In early 2012, it was discovered that intermittent androgen deprivation is equal in long-term survival to continuous androgen deprivation. A new paradigm of treatment, in which androgen deprivation was given for eight to nine months and then discontinued if the prostate specific antigen normalized, was published. Re-treatment is recommended only when the PSA level becomes greater than 10 with monitoring every two months.

SOURCES: 

American Cancer Society. 

National Cancer Institute. 

Cancer Research UK.  

News release, Astellas Pharma Inc.

UpToDate.

Reviewed by Jennifer Robinson on July 24, 2018

SOURCES: 

American Cancer Society. 

National Cancer Institute. 

Cancer Research UK.  

News release, Astellas Pharma Inc.

UpToDate.

Reviewed by Jennifer Robinson on July 24, 2018

NEXT QUESTION:

What are issues in combination therapy versus single-drug therapy for prostate cancer?

WAS THIS ANSWER HELPFUL

THIS TOOL DOES NOT PROVIDE MEDICAL ADVICE. It is intended for general informational purposes only and does not address individual circumstances. It is not a substitute for professional medical advice, diagnosis or treatment and should not be relied on to make decisions about your health. Never ignore professional medical advice in seeking treatment because of something you have read on the WebMD Site. If you think you may have a medical emergency, immediately call your doctor or dial 911.

    This tool does not provide medical advice. See additional information.